A new research note from Cantor Fitzgerald profiles stocks with upcoming earnings ... The company reports earnings on November 6. Myriad Genetics Inc. (NASDAQ: MYGN) is a biotech stock that has hammered the shorts so far this year, …
The latest FDA approval is expected to help the stock bounce back. Boston Scientific currently carries a Zacks Rank #3 (Hold). A few better-ranked medical …
... Having more Current Assets provides flexibility for MYGN. This also supports the short squeeze possibility. If you read my post on Accenture and how share buybacks create a floor to the stock price, MYGN has also been buying back …
Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that the NYSE's Listing and Compliance ... the NYSE Big Board in the second calendar quarter of 2009. Upon transfer the stock will trade under the new ticker symbol "MGX." …
MYGN maintains a pristine balance sheet with no debt and the ... driving market share and increasing growth in the company's stock price. Bevec wrote, "Given the breadth of the company's portfolio, TMO is essentially a one-stop shop …
Myriad Genetics Inc. (MYGN) reported fourth quarter EPS of $0.30 after the bell ... Shares finished up by 2.43 at $27.98 on above average volume. The stock broke out of a month and a half long trading range and set nearly a 52-week high.
Heading into today's session, the stock was boasting a nearly 12% year-to-date gain, and settled last night at $38.12. …
SmarTrend identified an Uptrend for Myriad Genetics (NASDAQ:MYGN) on May 3rd, 2017 at $21.49. In approximately 4 months, Myriad Genetics has returned 37.33% as of today's recent price of $29.52. Myriad Genetics share prices have …
Myriad Genetics Inc. MYGN reported adjusted earnings per share (EPS ... It has a four-quarter average earnings surprise of 8.45%. Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the …